公司産品2023年批簽發情況如下表：
The company's product 2023 annual batch issuance situation is as follows:
|
序号 Serial No. |
産品名稱 Product Name |
批次 Batch |
|
1 |
無細胞百白破b型流感嗜血杆菌聯合疫苗 Diphtheria, Tetanus, Acellular Pertussis and Haemophilus influenzae type b combined vaccine |
23批 23 batch |
|
2 |
23價肺炎球菌多(duō)糖疫苗 23-valent pneumococcal polysaccharide vaccine |
12批 12 batch |
|
3 |
13價肺炎球菌多(duō)糖結合疫苗（破傷風類毒素/白喉類毒素） 13- valent pneumococcal polysaccharide conjugate vaccine(TT/DT) |
15批 15 batch |
|
4 |
吸附無細胞百白破聯合疫苗 Diphtheria, Tetanus and Acellular Pertussis combined vaccine，Adsorbed |
11批 11 batch |
| 5 |
凍幹b型流感嗜血杆菌結合疫苗
Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried
|
4 批
4 batch
|
| 6 |
凍幹人(rén)用狂犬病疫苗（人(rén)二倍體(tǐ)細胞） Rabies Vaccine (Human Diploid Cell) for Human Use, Freeze-dried |
1 批
1 batch
|
批簽發公示：https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs
Batch release announcement:https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs